Introduction & Objective

- Lung cancer is the leading cause of cancer death worldwide. (1, 2 million cancer deaths, 23% of all cancer mortality (1.51 million new cases, 32.7% of all cancer cases) [1].
- Around 70% of NSCLC patients present with advanced or metastatic disease (T1-4N1-3M0) at the time of initial diagnosis (1-4).
- These patients either stage IIB NSCLC have a very poor prognosis with just about 7% of patients alive after 10 years [5-6].
- Chemotherapy is the most common treatment approach, and new agents for NSCLC are urgently needed (7-8). 

Methods

- In order to answer the research question the Italian healthcare settings setting has been selected exactly in order to compute the Italian therapy costs of erlotinib and generic docetaxel in NSCLG.
- These total therapy costs have been estimated by combining country-specific drug costs, administration costs, and costs of other erlotinib and docetaxel. The total cost data applied are shown in Table 2.

Results

- As shown in Figure 1 the total costs of therapy with erlotinib are €5,130 and the costs of generic docetaxel are €2,850.
- In order to validate the conclusion of the research, the incidence of the treatment adverse events and the costs related to the treatment adverse event have been calculated (8). This could be a significant opportunity to reduce costs and enhance the quality of care.
- The incidence of the treatment adverse events and the costs related to the treatment adverse event have been calculated (8). This could be a significant opportunity to reduce costs and enhance the quality of care.

Discussion

- The Italian healthcare system has been used in order to answer the research question: erlotinib.
- The incidence of the treatment adverse events and the costs related to the treatment adverse event have been calculated (8). This could be a significant opportunity to reduce costs and enhance the quality of care.
- The occurrence of the treatment adverse events and the costs related to the treatment adverse event have been calculated (8). This could be a significant opportunity to reduce costs and enhance the quality of care.

Conclusions

- The Italian healthcare system has been used in order to answer the research question on the incidence of the treatment adverse events and the costs related to the treatment adverse event have been calculated (8). This could be a significant opportunity to reduce costs and enhance the quality of care.
- The occurrence of the treatment adverse events and the costs related to the treatment adverse event have been calculated (8). This could be a significant opportunity to reduce costs and enhance the quality of care.
- In summary the present results have been very successful regarding the incidence of the treatment adverse events and the costs related to the treatment adverse event have been calculated (8). This could be a significant opportunity to reduce costs and enhance the quality of care.